Search Results

Nephron Pharmaceuticals Corporation announced the new hiring of six key executives.

NRx Pharmaceuticals, Inc. and Nephron Pharmaceuticals, Inc. announced the signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for treating suicidal depression, an urgent public health need.

Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer.

Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”) and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility.

Nephron Pharmaceuticals Corporation celebrated a successful $350 million capital raise – led by BlackRock Capital Investment Advisors, LLC and PNC Bank, National Association – to support future growth of the pharmaceutical manufacturer.

Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

Nephron Pharmaceuticals Corporation announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.

Nephron Pharmaceuticals Corporation announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.

Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced a new partnership focused on developing and sharing best practices in innovative manufacturing, product development, customer support, and quality as Nephron prepares to launch the Company’s InjectEZ component of expansion.

Sharps Technology, Inc. received a signed $30 million purchase order from Nephron Pharmaceuticals, representing their first 12 months of syringe purchase commitments.